As part of our ongoing aim to bring you reports of new developments, we have added a review on FIBRONEER-ILD which was a double-blind, randomised, placebo-controlled phase 3 trial which evaluated the efficacy and safety of nerandomilast (oral preferential PDE4B inhibitor) at doses of 18mg twice daily and 9mg twice daily, in the treatment of patients with progressive pulmonary fibrosis.
Independent commentary for the review has been provided by Professor Peter Youssef.
Please login below to download this issue (PDF)